Building on an R&D tie-up with an Indian stem cell institution last year, UK biotech PhoreMost has begun a collaboration with Japan’s Otsuka working on several gene therapy projects.
pharmaphorum’s Paul Tunnah spoke with Otsuka Pharmaceutical’s North America Pharmaceutical Business president and CEO Kabir Nath about the company’s innovative digital collaboration with Pr
This year’s eyeforpharma Barcelona conference might have seemed all doom and gloom at the outset, with many predicting the downfall of pharma as we know it – but there were plenty of speake
Otsuka is once again betting on digital as a new avenue for depression treatment by collaborating with Click Therapeutics to develop and commercialise a ‘prescriptio
Otsuka seems to think it’s onto something by using digital tech to aid treatment of mental health disorders: in November 2017 its Abilify MyCite, a combination of the company’s antipsychoti
Otsuka is paying $430 million for a US clinical-stage biotech company it hopes will act as a ‘drug creation engine’ to accelerate its research into kidney diseases.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.